---
title: "Chunli Medical's net profit last year was 270 million RMB, more than doubling, with revenue increasing by 30%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277381011.md"
description: "Chunli Medical announced its annual results for the year ending December 31, 2025, with a net profit of approximately RMB 270 million, an increase of 1.17 times compared to the previous year, and earnings per share of 71 cents. After deducting non-recurring gains and losses, the net profit was RMB 250 million, an increase of 1.7 times, with operating revenue of approximately RMB 1 billion, an increase of 29.5%. The company stated that with the advancement of national procurement for orthopedic consumables, product sales have steadily increased, and the scale of domestic business and market share continue to expand, while the international market is also continuously being developed"
datetime: "2026-03-02T00:40:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277381011.md)
  - [en](https://longbridge.com/en/news/277381011.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277381011.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277381011.md) | [English](https://longbridge.com/en/news/277381011.md)


# Chunli Medical's net profit last year was 270 million RMB, more than doubling, with revenue increasing by 30%

According to a report from Economic Information Daily on the 2nd, Chunli Medical (01858) (Shanghai: 688236) announced its preliminary results for the last fiscal year, with a net profit of approximately RMB 270 million for the year ending December 31, 2025, an increase of 1.17 times, and earnings per share of 71 cents.

The group stated that the net profit excluding non-recurring gains and losses was RMB 250 million, an increase of 1.7 times, with operating revenue of approximately RMB 1 billion, an increase of 29.5%. With the advancement of national procurement for orthopedic consumables, product sales have steadily increased, and the scale and market share of domestic business continue to expand, driving a steady improvement in profitability, as well as ongoing expansion and breakthroughs in international markets, leading to steady growth in overseas revenue. (wh)

\\\* For details regarding the performance, please refer to the company's official announcement

### 相關股票

- [CHUNLI MEDICAL (01858.HK)](https://longbridge.com/zh-HK/quote/01858.HK.md)
- [Chunli Medical (688236.CN)](https://longbridge.com/zh-HK/quote/688236.CN.md)

## 相關資訊與研究

- [Colombia oil production down 2.7% in February](https://longbridge.com/zh-HK/news/281030243.md)
- [VDC vs. IYK: Vanguard's Structural Advantage and IYK's Defensive Twist](https://longbridge.com/zh-HK/news/281591304.md)
- [New Zealand February building permits +2.7% m/m (prior +1.9%)](https://longbridge.com/zh-HK/news/281254036.md)
- [Financial Planning Navigators CORP Buys New Position in Sprott Physical Gold and Silver Trust $CEF](https://longbridge.com/zh-HK/news/281620776.md)
- [Kia's Global Sales in March Rise 2.7%](https://longbridge.com/zh-HK/news/281457352.md)